Nguyen May Thuy, Stoianovici Robyn, Brunetti Luigi
Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, New Brunswick, NJ, USA; Department of Pharmacy, Robert Wood Johnson University Hospital Somerset, Somerville, NJ, USA.
Department of Pharmacy, The University of Vermont Medical Center, Burlington, VT, USA.
Am J Emerg Med. 2017 Sep;35(9):1389-1390. doi: 10.1016/j.ajem.2017.07.022. Epub 2017 Jul 6.
Stroke mimics, especially those involving chemotherapy related neurotoxicity, can confound the clinical diagnosis of acute stroke. Here we describe the case of a 63year-old male with a recent history of stage IIIC colon cancer who presented with confusion on the second day of modified FOLFOX6 (5-fluorouracil/oxaliplatin) chemotherapy and subsequently received alteplase, tissue plasminogen activator therapy (tPA), for presumed ischemic stroke. Magnetic resonance imaging scans after tPA administration did not reveal evidence of an infarction and the patients' neurological symptoms resolved completely after discontinuation of 5-fluorouracil (5-FU). Although this patient did not experience any side effects from tPA, fibrinolytic therapy may have been avoided with a better understanding of potential chemotherapy related adverse reactions. Our experience suggests that 5-FU induced reversible encephalopathy can present with acute stroke-like symptoms and emergency medicine personnel evaluating patients for tPA treatment should be aware of this differential diagnosis.
类卒中,尤其是那些涉及化疗相关神经毒性的情况,可能会混淆急性卒中的临床诊断。在此,我们描述一例63岁男性病例,该患者近期有IIIC期结肠癌病史,在接受改良FOLFOX6(5-氟尿嘧啶/奥沙利铂)化疗的第二天出现意识模糊,随后因疑似缺血性卒中接受了阿替普酶(组织型纤溶酶原激活剂,tPA)治疗。给予tPA后进行的磁共振成像扫描未发现梗死迹象,停用5-氟尿嘧啶(5-FU)后患者的神经症状完全缓解。尽管该患者未出现tPA的任何副作用,但如果能更好地了解潜在的化疗相关不良反应,可能可以避免使用纤溶治疗。我们的经验表明,5-FU诱导的可逆性脑病可表现为急性卒中样症状,评估患者是否适合tPA治疗的急诊医护人员应了解这种鉴别诊断。